Technology evaluation: Sch-58500, Canji

Document Type

Article

Journal/Book Title/Conference

Technology evaluation: Sch-58500, Canji

Volume

2

Publication Date

2000

First Page

586

Last Page

92

Abstract

Sch-58500 is a gene therapy utilizing the p53 gene and is under development by Canji and Schering-Plough for the potential treatment of various types of cancer. It is in phase II/III clinical trials in the US for stage III ovarian cancer [328228,328893], phase II clinical trials for hepatocellular and colorectal cancer metastatic to the liver [273331,324279], and phase I clinical trials for several other types of cancer [282801,284932,328228].

Comments

Curr. Opin. Mol. Ther. 2000 2:586-92. PMID: 11249761

This document is currently not available here.

Share

COinS